Table 1.
Characteristics of patients undergoing related, HLA-identical, peripheral blood hematopoietic cell transplant, stratified for PTDM development
| Variable | No PTDM n= 9 (%) | PTDM n= 11 (%) | P-value |
|---|---|---|---|
| Median age, years (range) | 56 (30–61) | 55 (26–66) | 0.790 |
| Male | 6 (67) | 9 (82) | 0.617 |
| Caucasian ethnicity | 7 (78) | 10 (91) | 0.566 |
| Diabetes family history | 1 (11) | 4 (36) | 0.319 |
| Median pre-HCT BMI, kg/m2 (range) | 27.2 (22.4–48.9) | 30.3 (22.5–36.9) | 0.210 |
| Median day+90 BMI, kg/m2 (range) | 24.4 (19.8–46.3) | 28.7 (20.1–32.9) | 0.201 |
| Malignancy | |||
| Myeloid | 5 (56) | 7 (64) | 1.00 |
| AML/MDS (n= 8) | |||
| CML/MPN (n= 4) | |||
| Lymphoid | 4 (44) | 4 (36) | |
| NHL (n= 7) | |||
| CML lymphoid blast crisis (n= 1) | |||
| Pre-HCT steroid treatment | 3 (33) | 5 (45) | 0.67 |
| Chemotherapy | |||
| Myeloablative | 4 (44) | 4 (36) | 1.00 |
| Reduced intensity | 5 (56) | 7 (64) | |
| GVHD Prophylaxis | |||
| FK+MTX | 5 (56) | 7 (64) | 1.00 |
| FK+MMF | 4 (44) | 4 (36) | |
| Grade 2–4 acute GVHD | 4 (44)A | 5 (45)A | 1.00 |
| Steroid treatment first 100 days | 5 (56)B | 3 (27)B | 0.370 |
| Max steroid dose, mg/kg (range) | 0.4 (0.1–0.5) | 0.5 (0.1–1) | 0.539 |
| NIH mod-severe chronic GVHD | 5 (56) | 7 (64) | 1.00 |
Grade 2–4 GVHD treatment: systemic corticosteroids (prednisone or methylprednisolone) (n= 5), beclomethasone diproprionate and budesonide (n= 4).
Indications for systemic corticosteroid (prednisone or methylprednisolone) treatment: grade 1–4 GVHD (n= 6), pneumonitis/pleurisy (n= 1), and gout (n= 1).
PTDM, post-transplant diabetes mellitus; HCT, hematopoietic cell transplant; BMI, body mass index; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; MPN, myeloproliferative neoplasm; NHL, non-hodgkin’s lymphoma; FK, tacrolimus; MTX, methotrexate; MMF, mycophenolate mofetil; GVHD, graft-versus-host disease. NIH, National Institutes of Health; Mod, moderate.